Given that HDAC inhibitors have the capacity to ameliorate insulin resistance, we propose that these inhibitors may mitigate the progression of T2DM-CRC co-morbidity by enhancing insulin sensitivity. Here, HDAC9 is linked to colorectal carcinoma.